ArrePath获得2000万美元种子轮融资

March 6, 2022 0 Comments

ArrePath是一家抗感染药物研发商。致力于应对耐药性感染的全球健康挑战。近日宣布已完成2000万美元的种子轮融资,本轮融资由勃林格殷格翰风险基金(以下简称BIVF)、Insight Partners和Innospark Ventures联合领投,维亚生物、Arimed Capital、PTX Capital和Nor’easter Ventures跟投。

Leave a Reply

Your email address will not be published. Required fields are marked *